Award
NIH Reporter #5R44CA265510-05
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL)
Recipient
Not Specified
Award Amount
$2,409,283.00
Ceiling
$2,409,283.00
Awarded
July 11, 2025
Identifier
5R44CA265510-05
A clinical trial funded by the National Cancer Institute to test an antibody antagonist targeting TNFR2 for treating Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma, including pre-clinical validation and toxicology assessment.
Description
This project involves a clinical trial for an antibody antagonist targeting TNFR2, a receptor highly expressed in cancer tissue and immune suppressive cells. The trial aims to validate the therapeutic potential of BITR2101 in treating Non-Hodgkin Lymphoma (NHL) and Cutaneous T Cell Lymphoma (CTCL). The project includes extensive pre-clinical validation, GLP toxicology assessment, and aims to accelerate clinical use and market entry.